1. Registering for the Forum

    We require a human profile pic upon registration on this forum.

    After registration is submitted, you will receive a confirmation email, which should contain a link to confirm your intent to register for the forum. At this point, you will not yet be registered on the forum.

    Our Support staff will manually approve your account within 24 hours, and you will get a notification. This is to prevent the many spam account signups which we receive on a daily basis.

    If you have any problems completing this registration, please email support@jackkruse.com and we will assist you.

The 'mask'arade continues.......

Discussion in 'Educating Doctors' started by Jack Kruse, Nov 26, 2020.

  1. Jack Kruse

    Jack Kruse Administrator

    Dr. Bill Smith got arrested for refusing to wear a mask at a city council meeting (in Fayetteville, AR to defend the rights of the unvaccinated city employees who were going to be required to get tested weekly in order to keep their jobs), but his friends who were with him didn't want to get arrested.
    Bill Smith: 'That's the problem that we're facing. Very few people have the guts to stand up for what is right. We put up with our freedoms being taken away...I hope they find me guilty when I go to court. I'll spend 30 days in jail rather than pay the fines. We need to wake everyone up and throwing a doctor in jail because he wouldn't wear a mask should force people to admit that something is wrong."

    [​IMG]
     
    GavinH, Da-mo, caroline and 4 others like this.
  2. Freebird

    Freebird New Member

  3. Is coagulation disorder an outcome of the COVID injections?
    Relationship between blood eosinophil levels and COVID-19 mortality
    https://www.sciencedirect.com/science/article/pii/S1939455121000156

    Eosinophil levels in COVID-19 patients significantly and positively correlated with biomarkers of coagulation disorder.
    upload_2021-12-4_15-39-26.png
    Our data showed that eosinophil counts and ratios significantly and positively correlated with platelet counts (Fig. 3F), which was consistent with previous reports that eosinophils and platelets interacted with each other.17 In addition, eosinophil counts and ratios also significantly and positively correlated with D-dimer levels (Fig. 3F).​

    Eosinophil levels in COVID-19 patients significantly and inversely correlated with biomarkers of kidney injury.
    upload_2021-12-4_15-42-6.png
    Our analyses revealed that the patients with critical disease, when compared to those with moderate and severe diseases, displayed significantly increased serum levels of urea (Fig. 4A) and creatinine (Fig. 4B) but decreased estimated glomerular filtration rate (Fig. 4C), indicating kidney injury. Correlation analysis demonstrated that eosinophil counts and ratios significantly and inversely correlated with serum levels of urea and creatinine (Fig. 4D).​

    Eosinophil levels in COVID-19 patients significantly and inversely correlated with biomarkers of liver injury.
    upload_2021-12-4_15-43-41.png
    Patients with severe disease, when compared to those with moderate disease, showed significantly increased serum levels of aspartate aminotransferase (Fig. 5A) and alanine aminotransferase (Fig. 5B), indicating liver injury. In addition, patients with critical disease displayed further significantly increased serum levels of aspartate aminotransferase (Fig. 5A) but not those of alanine aminotransferase (Fig. 5B), suggesting worsening of liver injury in patients with critical disease. Correlation analyses demonstrated that eosinophil counts and ratios significantly and inversely correlated with serum levels of aspartate aminotransferase (Fig. 5C).​

    Our analyses revealed that eosinopenia correlated with biomarkers of coagulation disorder and those of tissue damage in kidney, liver, and other tissues.

    Question: Did you noticed - all these issues (disease states) - kidney, liver & other tissue damage are also listed in the VERSA outcome database as injuries from the COVID drug injections?

    Surprise, surprise - These "vaccines" are successfully transmitting the COVID virus passed the innate immune system into the general public.


    When evaluating the patterns of SARS-CoV-2 variants against the mass drug vaccination program(s), outcome data points to greater variants following each vaccination campaign typically 28 days passed the date of successfully vaccination status.
     
    Last edited: Dec 4, 2021
    Richard Watson likes this.
  4. :mad:
     
  5. How to scare people into obedience and medication? This problem - reaction - solution, is carefully planned.
    https://clinicaltrials.gov/ct2/show/NCT04460703?term=vaccine+messaging&draw=2&rank=2

    Study Type : Interventional (Clinical Trial)
    Actual Enrollment : 4000 participants
    Allocation: Randomized
    Intervention Model: Parallel Assignment
    Intervention Model Description: In this study, 2/15 of participants will be assigned to a control message (bird feeding passage), 3/15 of sample to a baseline vaccine message, and 1/15 to each of the 10 other treatment arms.
    Masking: None (Open Label)
    Primary Purpose: Other
    Official Title: Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1
     
    GavinH and Richard Watson like this.
  6. Da-mo

    Da-mo Gold

    The just released Pfizer document which is being circulated widely in the public domain and can downloaded from websites is entitled
    5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021

    https://docs.google.com/document/d/...UJrn1ygNdE_GM6pFpW0_srRs7i1tkGkKnURQCflZ7YjH8

    Guy David Hatchard Guy David Hatchard | Facebook
    Yestter1day18c gaioin9t 15ih:21r5e1 ·

    Document released by Pfizer apparently as a result of a Freedom Of Information court order in the USA reveals a vast array of previously unknown vaccine adverse effects compiled from official sources around the world

    Pfizer concedes this is ‘a large increase’ in adverse event reports and that even this huge volume is under reported
    Over 100+ diseases are listed, many very serious.

    This document was compiled by Pfizer in the very early days of the vaccine rollout in NZ but was possibly not supplied to our government
    We examine the implications for government

    Up until now, New Zealand GPs and hospitals have been provided with a fact sheet from Pfizer listing 21 possible adverse events as a result of vaccination. All of these are minor, requiring little or no treatment other than rest, with the exception of severe allergic reactions, myocarditis and pericarditis (inflammation of the heart). As a result, most of the many thousands of New Zealanders reporting adverse effects post vaccination have been sent home with little more than advice to take an aspirin and rest. Some have been told that their conditions may be unrelated medical events, psychosomatic, or due to anxiety on their part.
    Relying on the short official Pfizer fact sheet as a guide, Medsafe, our NZ medicines regulatory body, has only accepted one out of the 100+ deaths actually reported to them as related to vaccination. Most are listed as unrelated, under investigation, or unknowable. By contrast, the NZ Health Forum and other groups have collected unofficial reports of adverse effects and death proximate to vaccination. Out of 670+ reports of death compiled by the Forum, 270 have already been investigated by medical professionals and closely linked to known adverse effects. Following the publication of the new Pfizer document many more are expected to be connected with vaccination. Reports describe symptoms such as chest pain, brain fog, extreme fatigue, neurological symptoms, tachycardia, stroke, heart attacks, and many more. Collected data suggests that as many as two-thirds of adverse event enquiries made to medical staff by vaccine recipients have not been reported to CARM—the NZ system of adverse event reporting. Medsafe itself estimates in its Guide to Adverse Reaction Reporting that in NZ only 5% of adverse events are reported. As a result the NZ public is completely unaware of the extent of reported possible risks of vaccination.

    The just released Pfizer document which is being circulated widely in the public domain and can downloaded from websites is entitled
    5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021
    Therefore the reported side effects predate the vaccine rollout in New Zealand. The report itself was finalised by Pfizer on 30 April 2021. Did Pfizer supply this information to our government during the early days of our universal vaccination programme? If so the results should have been shared with our medical professionals, politicians, and the public. Many of the new 100+ listed new adverse event types now released by Pfizer in this 38 page document pose long term risks to health. Until very recently, the document was being withheld by Pfizer who maintained it should be kept confidential. There is a strong possibility that very large numbers of New Zealanders will suffer long term injury as a result.

    How did this happen without anyone’s knowledge?

    Even though the Pfizer vaccine had undergone very short trials and had provisional approval only, Medsafe did not update its CARM adverse event reporting system to make it mandatory rather than voluntary.


    Medsafe did not advise GPs and Hospital staff to be on high alert for adverse events and report them rapidly and in detail.
    The Government ignored the unprecedented numbers of adverse events being reported to Medsafe and circulating in the community and on social media.
    The Government instituted a public relations, promotional, and media campaign advising the public that the Pfizer covid-19 mRNA vaccine was completely safe and free of serious side effects, giving the impression that there were no side effects—not even the known serious effects of heart inflammation that Pfizer had already admitted.

    Unaccountably, conditions imposed by the contract that our Government signed with Pfizer for the supply of vaccines have not been made public. We suspect that the contract contains standard clauses similar to those used with drugs that have completed safety trials, such as a provision that public discussion of adverse events may only be undertaken in conjunction with the company supplying the drug. If this is the case, it will have hamstrung Medsafe and our Government in their approach to assessment and public discussion of adverse events.
    What are the new risks of vaccination?

    Anyone reading the new Pfizer adverse event report compilation will be staggered. The sheer density of the technical medical terms and disease names are nevertheless broken down into recognisable and serious categories of illness—kidney failure, stroke, cardiac events, pregnancy complications, inflammation, neurological disease, autoimmune failure, paralysis, liver failure, blood disorders, skin disease, musculoskeletal problems, arthritis, respiratory disease, DVT, blood clots, vascular disease, haemorrhage, loss of sight, Bell’s palsy, and epilepsy.

    How has this affected New Zealand?

    Whilst even the official Medsafe record of adverse effects and the unofficial lists show that the immediate risks of covid vaccination could be as much as 50 - 300 times greater than even the most risky of previous traditional vaccines (such as the smallpox jab), and whilst the long term effects are unknown, 90% of eligible New Zealanders have gone ahead with vaccination having accepted the assurances of safety and efficacy from the government, or having been forced to get vaccinated under threat of loss of employment and freedom of movement. Feeling the fear of covid that has been generated by reports in the international and local media, most people completing vaccination heaved a great sigh of relief—that is one huge worry off my mind, now I can get on with my life.

    Those finding that no immediate insurmountable reaction had surfaced (the majority) understandably agreed with the government: “What is all the fuss about? Why shouldn’t everyone do this, or be made to do this? It is a social good that will protect everyone”
    BUT there is a huge iceberg in the path of the good ship New Zealand hidden under the waves of relief. Thousands are quietly suffering debilitating illness, unacknowledged and in some cases untreated by their doctors. For those who survived vaccination without immediate injury this was not a problem because they didn’t know about it apart from one or two complaints from friends that might just be random coincidences.

    This has brought about a division in New Zealand society which the government created in the name of public safety. Thousands of dedicated servants of the nation including teachers, health workers, and others are being stigmatised and forced out of their jobs in a manner horrifyingly reminiscent of the treatment of Jews in Nazi Germany. The government did this despite knowing that the Pfizer vaccine was neither fully tested, safe, nor particularly effective. Judges handed down decisions in courts supporting the government mandates unaware of crucial mRNA vaccine safety data, all because Pfizer had withheld this information, and the government had not done its due diligence. Had the true position been known, the High Court’s NZ Bill of Rights analysis may well have been different and its provision which guarantees that every individual should be able to make their own medical choices might still be intact.

    Pfizer’s conclusions

    Pfizer concludes the released document with a statement “Review of the available data for this cumulative PM experience, confirms a favorable benefit:risk balance for BNT162b2.” PM stands for the Post Marketing data set they are evaluating of 42,086 reported adverse events. Pfizer makes this bald claim of benefit despite admitting that “the magnitude of underreporting is unknown”. This document contains no further substantive information in support of this claim of benefit:risk balance other than a mysterious reference to “the known safety profile of the vaccine”.
    The benefit:risk argument is in essence saying: covid-19 is a serious illness and our calculations show that more people will be injured by the disease than are being injured by the vaccine, therefore there will be a net benefit. This argument falls over because of at least three very important factors: Firstly treatment options have improved and thereby the risk of serious illness and death from covid has been greatly reduced.

    Secondly the risk of covid is not evenly spread. People with comorbidities (other conditions) and the elderly are at very high risk. Most other people are at very low risk. Thus vaccination could subject people at low risk from covid to a higher risk from vaccination. Approaches to preventive health education can reduce the covid risk to people with comorbidities more than vaccination can. For example a study published in the BMJ found that people following a plant based diet have a 73% reduced risk of serious illness. Data from the UK Biobank has been analysed by researchers from Manchester and Oxford Universities and the West Indies who found that shift workers (who typically have disrupted bioclocks) have three times the risk of being hospitalised with covid. Preventive remedies include changes in diet such as the introduction of more fresh fruit, vegetables, and fibre, and reductions in known unhealthy habits such as smoking, excess alcohol consumption, an overly sedentary lifestyle, a predominance of ultra processed foods, and many more.
    The third and most significant reason the benefit:risk argument falls over is the sheer range of adverse reaction types observed by Pfizer and kept hidden until now.

    How could a single vaccine have such a wide range of effects?

    The technical reasons why mRNA vaccines can have such broad effects on human health are understood by those working in gene therapy. Perfectly stable DNA function is critical to life. In turn, cell function integrity is critical to maintaining DNA. Individual cells contain mechanisms to repair their own DNA as many as 70,000 times a day. From this perspective, the in vitro laboratory study recently published in Viruses 2021, 13,2056, is indicative. It suggests a possible mechanism for vaccine harm. The study found that the spike protein localises in the nucleus and inhibits DNA damage repair by impeding access of key DNA repair proteins. The findings reveal a potential molecular pathway by which the covid spike protein might impede adaptive immunity. They underscore the potential side effects of the full-length spike-based mRNA vaccines.
    Despite a degree of cellular autonomy, the nervous system and the physiology must and does function as a whole. The entire nervous system including the immune system is a ‘part and whole’ network. The whole is in every part, the DNA is in every cell, but cell function is also related to a generalised and interconnected genetic network—the holistic functioning of the physiological network is critical to its efficiency. Thus physiological network stability (health) can be impaired by the introduction of pieces of active genetic code (biologic instructions) like those contained in mRNA vaccines.

    An analogy will make this clear. We are familiar with computer networks. A very common backbone of most commercial systems is produced by Microsoft. Each computer contains the Microsoft system and the network also runs under its system. The system is supported by computer code—a set of complex instructions written by Microsoft. Individual computers can perform standalone tasks and can communicate with other computers to keep the organisation running smoothly. This can be compared to the physiology. There are many systems in the body: immune system, circulatory system, digestive system, limbic system, homeostatic mechanisms, musculoskeletal structure, neural networks, and so on. They perform apparently stand alone functions, but all run on the basis of the same genetic code contained in our DNA and communicate with one another during the process of maintaining health. Back to our analogy: office staff sometimes send messages full of spelling errors to one another but this doesn’t harm the network. If however a computer virus written in code is sent by one computer it can overwhelm and crash network function because it affects the operating system. Some networks are protected by good firewalls and others are vulnerable. The Covid vaccine introduces a sequence of information written in genetic code into our physiology. It is no wonder that it could elicit such a very broad range of adverse effects, some of which are so serious as to be analogous to a computer network crash. Some individuals have strong immune systems and are little affected, others experience problems in one or other systems. The fact that a sequence of foreign code has been introduced into the physiology produces major risks to health, risks that those working in gene therapy for the last few decades are very familiar with.

    The extremely broad range of adverse effects revealed by the Pfizer document is the physiological signature of a general control system failure, a failure of the body’s overall integration and function. It is not plausible to suggest otherwise. That is why experts in genomics, even as I write, are pondering fundamental questions about the action and safety of mRNA vaccines. They are also urging caution.
    Conclusion

    The NZ government agreed commercial terms with a single company for vaccine supply. It is possible that vital information was withheld. The public was kept in ignorance of known risks. This has divided our society and undermined our fundamental Kiwi tolerance on the basis of not only incomplete but misleading safety data. The government is asleep at the wheel. Knowing full well that safety trials were incomplete, the government apparently accepted information supplied by multinational commercial interests at face value. This should be a ‘never again’ moment. There are huge lessons to be learned and an apology owed to the whole population. The provisions of the NZ BIll of Rights should be given constitutional status. The vaccine mandates should be withdrawn and those affected by them compensated. The proposed vaccination of 5 -11 year olds should be stopped.
     
    Last edited: Dec 5, 2021
    GavinH, Jacks, Richard Watson and 2 others like this.
  7. Da-mo

    Da-mo Gold

    APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST

    1p36 deletion syndrome;2-Hydroxyglutaric aciduria;5'nucleotidase increased;Acoustic neuritis;Acquired C1 inhibitor deficiency;Acquired epidermolysis bullosa;Acquired epileptic aphasia;Acute cutaneous lupus erythematosus;Acute disseminated encephalomyelitis;Acute

    encephalitis with refractory, repetitive partial seizures;Acute febrile neutrophilic dermatosis;Acute flaccid myelitis;Acute haemorrhagic leukoencephalitis;Acute haemorrhagic oedema of infancy;Acute kidney injury;Acute macular outer retinopathy;Acute motor axonal neuropathy;Acute motor-sensory axonal neuropathy;Acute myocardial infarction;Acute respiratory distress syndrome;Acute respiratory failure;Addison's disease;Administration site thrombosis;Administration site vasculitis;Adrenal thrombosis;Adverse event following immunisation;Ageusia;Agranulocytosis;Air embolism;Alanine aminotransferase abnormal;Alanine aminotransferase increased;Alcoholic seizure;Allergic bronchopulmonary mycosis;Allergic oedema;Alloimmune hepatitis;Alopecia areata;Alpers disease;Alveolar proteinosis;Ammonia abnormal;Ammonia increased;Amniotic cavity infection;Amygdalohippocampectomy;Amyloid arthropathy;Amyloidosis;Amyloidosis senile;Anaphylactic reaction;Anaphylactic shock;Anaphylactic transfusion reaction;Anaphylactoid reaction;Anaphylactoid shock;Anaphylactoid syndrome of pregnancy;Angioedema;Angiopathic neuropathy;Ankylosing spondylitis;Anosmia;Antiacetylcholine receptor antibody positive;Anti-actin antibody positive;Anti-aquaporin-4 antibody positive;Anti-basal ganglia antibody positive;Anti-cyclic citrullinated peptide antibody positive;Anti-epithelial antibody positive;Anti-erythrocyte antibody positive;Anti-exosome complex antibody positive;AntiGAD antibody negative;Anti-GAD antibody positive;Anti-ganglioside antibody positive;Antigliadin antibody positive;Anti-glomerular basement membrane antibody positive;Anti-glomerular basement membrane disease;Anti-glycyl-tRNA synthetase antibody positive;Anti-HLA antibody test positive;Anti-IA2 antibody positive;Anti-insulin antibody increased;Anti-insulin antibody positive;Anti-insulin receptor antibody increased;Antiinsulin receptor antibody positive;Anti-interferon antibody negative;Anti-interferon antibody positive;Anti-islet cell antibody positive;Antimitochondrial antibody positive;Anti-muscle specific kinase antibody positive;Anti-myelin-associated glycoprotein antibodies positive;Anti-myelin-associated glycoprotein associated polyneuropathy;Antimyocardial antibody positive;Anti-neuronal antibody positive;Antineutrophil cytoplasmic antibody increased;Antineutrophil cytoplasmic antibody positive;Anti-neutrophil cytoplasmic antibody positive vasculitis;Anti-NMDA antibody positive;Antinuclear antibody increased;Antinuclear antibody positive;Antiphospholipid antibodies positive;Antiphospholipid syndrome;Anti-platelet antibody positive;Anti-prothrombin antibody positive;Antiribosomal P antibody positive;Anti-RNA polymerase III antibody positive;Anti-saccharomyces cerevisiae antibody test positive;Anti-sperm antibody positive;Anti-SRP antibody positive;Antisynthetase syndrome;Anti-thyroid antibody positive;Anti-transglutaminase antibody increased;Anti-VGCC antibody positive;AntiVGKC antibody positive;Anti-vimentin antibody positive;Antiviral prophylaxis;Antiviral treatment;Anti-zinc transporter 8 antibody positive;Aortic embolus;Aortic thrombosis;Aortitis;Aplasia pure red cell;Aplastic anaemia;Application site thrombosis;Application site vasculitis;Arrhythmia;Arterial bypass occlusion;Arterial bypass thrombosis;Arterial thrombosis;Arteriovenous fistula thrombosis;Arteriovenous graft site stenosis;Arteriovenous graft thrombosis;Arteritis;Arteritis

    FDA-CBER-2021-5683-0000083

    Page 30

    coronary;Arthralgia;Arthritis;Arthritis enteropathic;Ascites;Aseptic cavernous sinus thrombosis;Aspartate aminotransferase abnormal;Aspartate aminotransferase

    increased;Aspartate-glutamate-transporter deficiency;AST to platelet ratio index

    increased;AST/ALT ratio abnormal;Asthma;Asymptomatic COVID-

    19;Ataxia;Atheroembolism;Atonic seizures;Atrial thrombosis;Atrophic thyroiditis;Atypical benign partial epilepsy;Atypical pneumonia;Aura;Autoantibody positive;Autoimmune anaemia;Autoimmune aplastic anaemia;Autoimmune arthritis;Autoimmune blistering disease;Autoimmune cholangitis;Autoimmune colitis;Autoimmune demyelinating disease;Autoimmune dermatitis;Autoimmune disorder;Autoimmune

    encephalopathy;Autoimmune endocrine disorder;Autoimmune enteropathy;Autoimmune eye disorder;Autoimmune haemolytic anaemia;Autoimmune heparin-induced thrombocytopenia;Autoimmune hepatitis;Autoimmune hyperlipidaemia;Autoimmune hypothyroidism;Autoimmune inner ear disease;Autoimmune lung disease;Autoimmune lymphoproliferative syndrome;Autoimmune myocarditis;Autoimmune myositis;Autoimmune nephritis;Autoimmune neuropathy;Autoimmune neutropenia;Autoimmune pancreatitis;Autoimmune pancytopenia;Autoimmune pericarditis;Autoimmune retinopathy;Autoimmune thyroid disorder;Autoimmune thyroiditis;Autoimmune uveitis;Autoinflammation with infantile enterocolitis;Autoinflammatory disease;Automatism epileptic;Autonomic nervous system imbalance;Autonomic seizure;Axial spondyloarthritis;Axillary vein thrombosis;Axonal and demyelinating polyneuropathy;Axonal neuropathy;Bacterascites;Baltic myoclonic epilepsy;Band sensation;Basedow's disease;Basilar artery thrombosis;Basophilopenia;B-cell aplasia;Behcet's syndrome;Benign ethnic neutropenia;Benign familial neonatal convulsions;Benign familial pemphigus;Benign rolandic epilepsy;Beta-2 glycoprotein antibody positive;Bickerstaff's encephalitis;Bile output abnormal;Bile output decreased;Biliary ascites;Bilirubin conjugated abnormal;Bilirubin conjugated increased;Bilirubin urine present;Biopsy liver abnormal;Biotinidase deficiency;Birdshot chorioretinopathy;Blood alkaline phosphatase abnormal;Blood alkaline phosphatase increased;Blood bilirubin abnormal;Blood bilirubin increased;Blood bilirubin unconjugated increased;Blood cholinesterase abnormal;Blood cholinesterase decreased;Blood pressure decreased;Blood pressure diastolic decreased;Blood pressure systolic decreased;Blue toe syndrome;Brachiocephalic vein thrombosis;Brain stem embolism;Brain stem thrombosis;Bromosulphthalein test abnormal;Bronchial oedema;Bronchitis;Bronchitis mycoplasmal;Bronchitis viral;Bronchopulmonary aspergillosis allergic;Bronchospasm;BuddChiari syndrome;Bulbar palsy;Butterfly rash;C1q nephropathy;Caesarean section;Calcium embolism;Capillaritis;Caplan's syndrome;Cardiac amyloidosis;Cardiac arrest;Cardiac failure;Cardiac failure acute;Cardiac sarcoidosis;Cardiac ventricular thrombosis;Cardiogenic shock;Cardiolipin antibody positive;Cardiopulmonary failure;Cardio-respiratory arrest;Cardio-respiratory distress;Cardiovascular insufficiency;Carotid arterial embolus;Carotid artery thrombosis;Cataplexy;Catheter site thrombosis;Catheter site vasculitis;Cavernous sinus thrombosis;CDKL5 deficiency disorder;CEC syndrome;Cement embolism;Central nervous system lupus;Central nervous system vasculitis;Cerebellar artery thrombosis;Cerebellar embolism;Cerebral amyloid angiopathy;Cerebral arteritis;Cerebral artery embolism;Cerebral artery thrombosis;Cerebral gas embolism;Cerebral microembolism;Cerebral septic infarct;Cerebral thrombosis;Cerebral venous sinus thrombosis;Cerebral venous thrombosis;Cerebrospinal thrombotic

    FDA-CBER-2021-5683-0000084

    Page 31

    tamponade;Cerebrovascular accident;Change in seizure presentation;Chest discomfort;ChildPugh-Turcotte score abnormal;Child-Pugh-Turcotte score increased;Chillblains;Choking;Choking sensation;Cholangitis sclerosing;Chronic autoimmune glomerulonephritis;Chronic cutaneous lupus erythematosus;Chronic fatigue syndrome;Chronic gastritis;Chronic inflammatory demyelinating polyradiculoneuropathy;Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids;Chronic recurrent multifocal osteomyelitis;Chronic respiratory failure;Chronic spontaneous urticaria;Circulatory collapse;Circumoral oedema;Circumoral swelling;Clinically isolated syndrome;Clonic convulsion;Coeliac disease;Cogan's syndrome;Cold agglutinins positive;Cold type haemolytic anaemia;Colitis;Colitis erosive;Colitis herpes;Colitis microscopic;Colitis ulcerative;Collagen disorder;Collagen-vascular disease;Complement factor abnormal;Complement factor C1 decreased;Complement factor C2 decreased;Complement factor C3 decreased;Complement factor C4 decreased;Complement factor decreased;Computerised tomogram liver abnormal;Concentric sclerosis;Congenital anomaly;Congenital bilateral perisylvian syndrome;Congenital herpes simplex infection;Congenital myasthenic syndrome;Congenital varicella infection;Congestive hepatopathy;Convulsion in childhood;Convulsions local;Convulsive threshold lowered;Coombs positive haemolytic anaemia;Coronary artery disease;Coronary artery embolism;Coronary artery thrombosis;Coronary bypass thrombosis;Coronavirus infection;Coronavirus test;Coronavirus test negative;Coronavirus test positive;Corpus callosotomy;Cough;Cough variant asthma;COVID-19;COVID-19 immunisation;COVID-19 pneumonia;COVID-19 prophylaxis;COVID-19 treatment;Cranial nerve disorder;Cranial nerve palsies multiple;Cranial nerve paralysis;CREST syndrome;Crohn's disease;Cryofibrinogenaemia;Cryoglobulinaemia;CSF oligoclonal band present;CSWS syndrome;Cutaneous amyloidosis;Cutaneous lupus erythematosus;Cutaneous sarcoidosis;Cutaneous vasculitis;Cyanosis;Cyclic neutropenia;Cystitis interstitial;Cytokine release syndrome;Cytokine storm;De novo purine synthesis inhibitors associated acute inflammatory syndrome;Death neonatal;Deep vein thrombosis;Deep vein thrombosis postoperative;Deficiency of bile secretion;Deja vu;Demyelinating polyneuropathy;Demyelination;Dermatitis;Dermatitis bullous;Dermatitis herpetiformis;Dermatomyositis;Device embolisation;Device related thrombosis;Diabetes mellitus;Diabetic ketoacidosis;Diabetic mastopathy;Dialysis amyloidosis;Dialysis membrane reaction;Diastolic hypotension;Diffuse vasculitis;Digital pitting scar;Disseminated intravascular coagulation;Disseminated intravascular coagulation in newborn;Disseminated neonatal herpes simplex;Disseminated varicella;Disseminated varicella zoster vaccine virus infection;Disseminated varicella zoster virus infection;DNA antibody positive;Double cortex syndrome;Double stranded DNA antibody positive;Dreamy state;Dressler's syndrome;Drop attacks;Drug withdrawal convulsions;Dyspnoea;Early infantile epileptic encephalopathy with burst-suppression;Eclampsia;Eczema herpeticum;Embolia cutis medicamentosa;Embolic cerebellar infarction;Embolic cerebral infarction;Embolic pneumonia;Embolic stroke;Embolism;Embolism arterial;Embolism venous;Encephalitis;Encephalitis allergic;Encephalitis autoimmune;Encephalitis brain stem;Encephalitis haemorrhagic;Encephalitis periaxialis diffusa;Encephalitis post immunisation;Encephalomyelitis;Encephalopathy;Endocrine disorder;Endocrine ophthalmopathy;Endotracheal intubation;Enteritis;Enteritis leukopenic;Enterobacter pneumonia;Enterocolitis;Enteropathic spondylitis;Eosinopenia;Eosinophilic

    FDA-CBER-2021-5683-0000085

    Page 32

    fasciitis;Eosinophilic granulomatosis with polyangiitis;Eosinophilic oesophagitis;Epidermolysis;Epilepsy;Epilepsy surgery;Epilepsy with myoclonic-atonic seizures;Epileptic aura;Epileptic psychosis;Erythema;Erythema induratum;Erythema multiforme;Erythema nodosum;Evans syndrome;Exanthema subitum;Expanded disability status scale score decreased;Expanded disability status scale score increased;Exposure to communicable disease;Exposure to SARS-CoV-2;Eye oedema;Eye pruritus;Eye swelling;Eyelid oedema;Face oedema;Facial paralysis;Facial paresis;Faciobrachial dystonic seizure;Fat embolism;Febrile convulsion;Febrile infection-related epilepsy syndrome;Febrile neutropenia;Felty's syndrome;Femoral artery embolism;Fibrillary glomerulonephritis;Fibromyalgia;Flushing;Foaming at mouth;Focal cortical resection;Focal dyscognitive seizures;Foetal distress syndrome;Foetal placental thrombosis;Foetor hepaticus;Foreign body embolism;Frontal lobe epilepsy;Fulminant type 1 diabetes mellitus;Galactose elimination capacity test abnormal;Galactose elimination capacity test decreased;Gamma-glutamyltransferase abnormal;Gamma-glutamyltransferase increased;Gastritis herpes;Gastrointestinal amyloidosis;Gelastic seizure;Generalised onset non-motor seizure;Generalised tonic-clonic seizure;Genital herpes;Genital herpes simplex;Genital herpes zoster;Giant cell arteritis;Glomerulonephritis;Glomerulonephritis membranoproliferative;Glomerulonephritis membranous;Glomerulonephritis rapidly progressive;Glossopharyngeal nerve paralysis;Glucose transporter type 1 deficiency syndrome;Glutamate dehydrogenase increased;Glycocholic acid increased;GM2 gangliosidosis;Goodpasture's syndrome;Graft

    thrombosis;Granulocytopenia;Granulocytopenia neonatal;Granulomatosis with

    polyangiitis;Granulomatous dermatitis;Grey matter heterotopia;Guanase increased;GuillainBarre syndrome;Haemolytic anaemia;Haemophagocytic

    lymphohistiocytosis;Haemorrhage;Haemorrhagic ascites;Haemorrhagic disorder;Haemorrhagic pneumonia;Haemorrhagic varicella syndrome;Haemorrhagic vasculitis;Hantavirus pulmonary infection;Hashimoto's encephalopathy;Hashitoxicosis;Hemimegalencephaly;Henoch-Schonlein purpura;HenochSchonlein purpura nephritis;Hepaplastin abnormal;Hepaplastin decreased;Heparin-induced thrombocytopenia;Hepatic amyloidosis;Hepatic artery embolism;Hepatic artery flow decreased;Hepatic artery thrombosis;Hepatic enzyme abnormal;Hepatic enzyme decreased;Hepatic enzyme increased;Hepatic fibrosis marker abnormal;Hepatic fibrosis marker increased;Hepatic function abnormal;Hepatic hydrothorax;Hepatic hypertrophy;Hepatic hypoperfusion;Hepatic lymphocytic infiltration;Hepatic mass;Hepatic pain;Hepatic sequestration;Hepatic vascular resistance increased;Hepatic vascular thrombosis;Hepatic vein embolism;Hepatic vein thrombosis;Hepatic venous pressure gradient abnormal;Hepatic venous pressure gradient increased;Hepatitis;Hepatobiliary scan abnormal;Hepatomegaly;Hepatosplenomegaly;Hereditary angioedema with C1 esterase inhibitor deficiency;Herpes dermatitis;Herpes gestationis;Herpes oesophagitis;Herpes ophthalmic;Herpes pharyngitis;Herpes sepsis;Herpes simplex;Herpes simplex cervicitis;Herpes simplex colitis;Herpes simplex encephalitis;Herpes simplex gastritis;Herpes simplex hepatitis;Herpes simplex meningitis;Herpes simplex meningoencephalitis;Herpes simplex meningomyelitis;Herpes simplex necrotising retinopathy;Herpes simplex oesophagitis;Herpes simplex otitis externa;Herpes simplex pharyngitis;Herpes simplex pneumonia;Herpes simplex reactivation;Herpes simplex sepsis;Herpes simplex viraemia;Herpes simplex virus conjunctivitis neonatal;Herpes simplex visceral;Herpes virus

    FDA-CBER-2021-5683-0000086
     
    Johan Lindstrøm likes this.
  8. Da-mo

    Da-mo Gold

    Page 33

    infection;Herpes zoster;Herpes zoster cutaneous disseminated;Herpes zoster infection neurological;Herpes zoster meningitis;Herpes zoster meningoencephalitis;Herpes zoster meningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster necrotising retinopathy;Herpes zoster oticus;Herpes zoster pharyngitis;Herpes zoster reactivation;Herpetic radiculopathy;Histone antibody positive;Hoigne's syndrome;Human herpesvirus 6 encephalitis;Human herpesvirus 6 infection;Human herpesvirus 6 infection reactivation;Human herpesvirus 7 infection;Human herpesvirus 8 infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemia benign monoclonal;Hyperglycaemic seizure;Hypersensitivity;Hypersensitivity vasculitis;Hyperthyroidism;Hypertransaminasaemia;Hyperventilation;Hypoalbuminaemia;H ypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve paralysis;Hypoglossal nerve paresis;Hypoglycaemic seizure;Hyponatraemic seizure;Hypotension;Hypotensive crisis;Hypothenar hammer syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4 lymphocytopenia;Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathic neutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM nephropathy;IIIrd nerve paralysis;IIIrd nerve paresis;Iliac artery embolism;Immune thrombocytopenia;Immunemediated adverse reaction;Immune-mediated cholangitis;Immune-mediated cholestasis;Immune-mediated cytopenia;Immune-mediated encephalitis;Immune-mediated encephalopathy;Immune-mediated endocrinopathy;Immune-mediated enterocolitis;Immunemediated gastritis;Immune-mediated hepatic disorder;Immune-mediated hepatitis;Immunemediated hyperthyroidism;Immune-mediated hypothyroidism;Immune-mediated myocarditis;Immune-mediated myositis;Immune-mediated nephritis;Immune-mediated neuropathy;Immune-mediated pancreatitis;Immune-mediated pneumonitis;Immune-mediated renal disorder;Immune-mediated thyroiditis;Immune-mediated uveitis;Immunoglobulin G4 related disease;Immunoglobulins abnormal;Implant site thrombosis;Inclusion body myositis;Infantile genetic agranulocytosis;Infantile spasms;Infected vasculitis;Infective thrombosis;Inflammation;Inflammatory bowel disease;Infusion site thrombosis;Infusion site vasculitis;Injection site thrombosis;Injection site urticaria;Injection site vasculitis;Instillation

    site thrombosis;Insulin autoimmune syndrome;Interstitial granulomatous dermatitis;Interstitial lung disease;Intracardiac mass;Intracardiac thrombus;Intracranial pressure increased;Intrapericardial thrombosis;Intrinsic factor antibody abnormal;Intrinsic factor antibody positive;IPEX syndrome;Irregular breathing;IRVAN syndrome;IVth nerve paralysis;IVth nerve paresis;JC polyomavirus test positive;JC virus CSF test positive;Jeavons syndrome;Jugular vein embolism;Jugular vein thrombosis;Juvenile idiopathic arthritis;Juvenile myoclonic epilepsy;Juvenile polymyositis;Juvenile psoriatic arthritis;Juvenile spondyloarthritis;Kaposi sarcoma inflammatory cytokine syndrome;Kawasaki's disease;Kayser-Fleischer ring;Keratoderma blenorrhagica;Ketosisprone diabetes mellitus;Kounis syndrome;Lafora's myoclonic epilepsy;Lambl's excrescences;Laryngeal dyspnoea;Laryngeal oedema;Laryngeal rheumatoid arthritis;Laryngospasm;Laryngotracheal oedema;Latent autoimmune diabetes in adults;LE cells present;Lemierre syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidase increased;Leukoencephalomyelitis;Leukoencephalopathy;Leukopenia;Leukopenia neonatal;Lewis-Sumner syndrome;Lhermitte's sign;Lichen planopilaris;Lichen planus;Lichen sclerosus;Limbic encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver function test abnormal;Liver function test decreased;Liver function test increased;Liver induration;Liver injury;Liver iron concentration abnormal;Liver iron concentration

    FDA-CBER-2021-5683-0000087

    Page 34

    increased;Liver opacity;Liver palpable;Liver sarcoidosis;Liver scan abnormal;Liver tenderness;Low birth weight baby;Lower respiratory tract herpes infection;Lower respiratory tract infection;Lower respiratory tract infection viral;Lung abscess;Lupoid hepatic cirrhosis;Lupus cystitis;Lupus encephalitis;Lupus endocarditis;Lupus enteritis;Lupus hepatitis;Lupus myocarditis;Lupus myositis;Lupus nephritis;Lupus pancreatitis;Lupus pleurisy;Lupus pneumonitis;Lupus vasculitis;Lupus-like syndrome;Lymphocytic hypophysitis;Lymphocytopenia neonatal;Lymphopenia;MAGIC syndrome;Magnetic resonance imaging liver abnormal;Magnetic resonance proton density fat fraction measurement;Mahler sign;Manufacturing laboratory analytical testing issue;Manufacturing materials issue;Manufacturing production issue;Marburg's variant multiple sclerosis;Marchiafava-Bignami disease;Marine Lenhart syndrome;Mastocytic enterocolitis;Maternal exposure during pregnancy;Medical device site thrombosis;Medical device site vasculitis;MELAS syndrome;Meningitis;Meningitis aseptic;Meningitis herpes;Meningoencephalitis herpes simplex neonatal;Meningoencephalitis herpetic;Meningomyelitis herpes;MERS-CoV test;MERS-CoV test negative;MERS-CoV test positive;Mesangioproliferative glomerulonephritis;Mesenteric artery embolism;Mesenteric artery thrombosis;Mesenteric vein thrombosis;Metapneumovirus infection;Metastatic cutaneous Crohn's disease;Metastatic pulmonary embolism;Microangiopathy;Microembolism;Microscopic polyangiitis;Middle East respiratory syndrome;Migraine-triggered seizure;Miliary pneumonia;Miller Fisher syndrome;Mitochondrial aspartate aminotransferase increased;Mixed connective tissue disease;Model for end stage liver disease score abnormal;Model for end stage liver disease score increased;Molar ratio of total branched-chain amino acid to tyrosine;Molybdenum cofactor deficiency;Monocytopenia;Mononeuritis;Mononeuropathy multiplex;Morphoea;Morvan syndrome;Mouth swelling;Moyamoya disease;Multifocal motor neuropathy;Multiple organ dysfunction syndrome;Multiple sclerosis;Multiple sclerosis relapse;Multiple sclerosis relapse prophylaxis;Multiple subpial transection;Multisystem inflammatory syndrome in children;Muscular sarcoidosis;Myasthenia gravis;Myasthenia gravis crisis;Myasthenia gravis neonatal;Myasthenic syndrome;Myelitis;Myelitis transverse;Myocardial infarction;Myocarditis;Myocarditis post infection;Myoclonic epilepsy;Myoclonic epilepsy and ragged-red fibres;Myokymia;Myositis;Narcolepsy;Nasal herpes;Nasal obstruction;Necrotising herpetic retinopathy;Neonatal Crohn's disease;Neonatal epileptic seizure;Neonatal lupus erythematosus;Neonatal mucocutaneous herpes simplex;Neonatal pneumonia;Neonatal seizure;Nephritis;Nephrogenic systemic fibrosis;Neuralgic amyotrophy;Neuritis;Neuritis cranial;Neuromyelitis optica pseudo relapse;Neuromyelitis optica spectrum disorder;Neuromyotonia;Neuronal neuropathy;Neuropathy peripheral;Neuropathy, ataxia, retinitis pigmentosa syndrome;Neuropsychiatric lupus;Neurosarcoidosis;Neutropenia;Neutropenia neonatal;Neutropenic colitis;Neutropenic infection;Neutropenic sepsis;Nodular rash;Nodular vasculitis;Noninfectious myelitis;Noninfective encephalitis;Noninfective encephalomyelitis;Noninfective oophoritis;Obstetrical pulmonary embolism;Occupational exposure to communicable disease;Occupational exposure to SARS-CoV-2;Ocular hyperaemia;Ocular myasthenia;Ocular pemphigoid;Ocular sarcoidosis;Ocular vasculitis;Oculofacial paralysis;Oedema;Oedema blister;Oedema due to hepatic disease;Oedema mouth;Oesophageal achalasia;Ophthalmic artery thrombosis;Ophthalmic herpes simplex;Ophthalmic herpes zoster;Ophthalmic vein thrombosis;Optic neuritis;Optic

    FDA-CBER-2021-5683-0000088

    Page 35

    neuropathy;Optic perineuritis;Oral herpes;Oral lichen planus;Oropharyngeal oedema;Oropharyngeal spasm;Oropharyngeal swelling;Osmotic demyelination syndrome;Ovarian vein thrombosis;Overlap syndrome;Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection;Paget-Schroetter syndrome;Palindromic rheumatism;Palisaded neutrophilic granulomatous dermatitis;Palmoplantar keratoderma;Palpable purpura;Pancreatitis;Panencephalitis;Papillophlebitis;Paracancerous pneumonia;Paradoxical embolism;Parainfluenzae viral laryngotracheobronchitis;Paraneoplastic dermatomyositis;Paraneoplastic pemphigus;Paraneoplastic thrombosis;Paresis cranial nerve;Parietal cell antibody positive;Paroxysmal nocturnal haemoglobinuria;Partial seizures;Partial seizures with secondary generalisation;Patient isolation;Pelvic venous thrombosis;Pemphigoid;Pemphigus;Penile vein thrombosis;Pericarditis;Pericarditis lupus;Perihepatic discomfort;Periorbital oedema;Periorbital swelling;Peripheral artery thrombosis;Peripheral embolism;Peripheral ischaemia;Peripheral vein thrombus extension;Periportal oedema;Peritoneal fluid protein abnormal;Peritoneal fluid protein decreased;Peritoneal fluid protein increased;Peritonitis lupus;Pernicious anaemia;Petit mal epilepsy;Pharyngeal oedema;Pharyngeal swelling;Pityriasis lichenoides et varioliformis acuta;Placenta praevia;Pleuroparenchymal fibroelastosis;Pneumobilia;Pneumonia;Pneumonia adenoviral;Pneumonia cytomegaloviral;Pneumonia herpes viral;Pneumonia influenzal;Pneumonia measles;Pneumonia mycoplasmal;Pneumonia necrotising;Pneumonia parainfluenzae viral;Pneumonia respiratory syncytial viral;Pneumonia viral;POEMS syndrome;Polyarteritis nodosa;Polyarthritis;Polychondritis;Polyglandular autoimmune syndrome type I;Polyglandular autoimmune syndrome type II;Polyglandular autoimmune syndrome type III;Polyglandular disorder;Polymicrogyria;Polymyalgia rheumatica;Polymyositis;Polyneuropathy;Polyneuropathy idiopathic progressive;Portal pyaemia;Portal vein embolism;Portal vein flow decreased;Portal vein pressure increased;Portal vein thrombosis;Portosplenomesenteric venous thrombosis;Post procedural hypotension;Post procedural pneumonia;Post procedural pulmonary embolism;Post stroke epilepsy;Post stroke seizure;Post thrombotic retinopathy;Post thrombotic syndrome;Post viral fatigue syndrome;Postictal headache;Postictal paralysis;Postictal psychosis;Postictal state;Postoperative respiratory distress;Postoperative respiratory failure;Postoperative thrombosis;Postpartum thrombosis;Postpartum venous thrombosis;Postpericardiotomy syndrome;Post-traumatic epilepsy;Postural orthostatic tachycardia syndrome;Precerebral artery thrombosis;Pre-eclampsia;Preictal state;Premature labour;Premature menopause;Primary amyloidosis;Primary biliary cholangitis;Primary progressive multiple sclerosis;Procedural shock;Proctitis herpes;Proctitis ulcerative;Product availability issue;Product distribution issue;Product supply issue;Progressive facial hemiatrophy;Progressive multifocal leukoencephalopathy;Progressive multiple sclerosis;Progressive relapsing multiple sclerosis;Prosthetic cardiac valve thrombosis;Pruritus;Pruritus allergic;Pseudovasculitis;Psoriasis;Psoriatic arthropathy;Pulmonary amyloidosis;Pulmonary artery thrombosis;Pulmonary embolism;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary microemboli;Pulmonary oil microembolism;Pulmonary renal syndrome;Pulmonary sarcoidosis;Pulmonary sepsis;Pulmonary thrombosis;Pulmonary tumour thrombotic microangiopathy;Pulmonary vasculitis;Pulmonary veno-occlusive disease;Pulmonary venous thrombosis;Pyoderma gangrenosum;Pyostomatitis vegetans;Pyrexia;Quarantine;Radiation leukopenia;Radiculitis

    FDA-CBER-2021-5683-0000089

    Page 36

    brachial;Radiologically isolated syndrome;Rash;Rash erythematous;Rash pruritic;Rasmussen encephalitis;Raynaud's phenomenon;Reactive capillary endothelial proliferation;Relapsing multiple sclerosis;Relapsing-remitting multiple sclerosis;Renal amyloidosis;Renal arteritis;Renal artery thrombosis;Renal embolism;Renal failure;Renal vascular thrombosis;Renal vasculitis;Renal vein embolism;Renal vein thrombosis;Respiratory arrest;Respiratory disorder;Respiratory distress;Respiratory failure;Respiratory paralysis;Respiratory syncytial virus bronchiolitis;Respiratory syncytial virus bronchitis;Retinal artery embolism;Retinal artery occlusion;Retinal artery thrombosis;Retinal vascular thrombosis;Retinal vasculitis;Retinal vein occlusion;Retinal vein thrombosis;Retinol binding protein decreased;Retinopathy;Retrograde portal vein flow;Retroperitoneal fibrosis;Reversible airways obstruction;Reynold's syndrome;Rheumatic brain disease;Rheumatic disorder;Rheumatoid arthritis;Rheumatoid factor increased;Rheumatoid factor positive;Rheumatoid factor quantitative increased;Rheumatoid lung;Rheumatoid neutrophilic dermatosis;Rheumatoid nodule;Rheumatoid nodule removal;Rheumatoid scleritis;Rheumatoid vasculitis;Saccadic eye movement;SAPHO syndrome;Sarcoidosis;SARS-CoV-1 test;SARS-CoV-1 test negative;SARS-CoV-1 test positive;SARS-CoV-2 antibody test;SARS-CoV-2 antibody test negative;SARS-CoV-2 antibody test positive;SARS-CoV-2 carrier;SARS-CoV-2 sepsis;SARS-CoV-2 test;SARSCoV-2 test false negative;SARS-CoV-2 test false positive;SARS-CoV-2 test negative;SARSCoV-2 test positive;SARS-CoV-2 viraemia;Satoyoshi

    syndrome;Schizencephaly;Scleritis;Sclerodactylia;Scleroderma;Scleroderma associated digital ulcer;Scleroderma renal crisis;Scleroderma-like reaction;Secondary amyloidosis;Secondary cerebellar degeneration;Secondary progressive multiple sclerosis;Segmented hyalinising vasculitis;Seizure;Seizure anoxic;Seizure cluster;Seizure like phenomena;Seizure prophylaxis;Sensation of foreign body;Septic embolus;Septic pulmonary embolism;Severe acute respiratory syndrome;Severe myoclonic epilepsy of infancy;Shock;Shock symptom;Shrinking lung syndrome;Shunt thrombosis;Silent thyroiditis;Simple partial seizures;Sjogren's syndrome;Skin swelling;SLE arthritis;Smooth muscle antibody positive;Sneezing;Spinal artery embolism;Spinal artery thrombosis;Splenic artery thrombosis;Splenic embolism;Splenic thrombosis;Splenic vein thrombosis;Spondylitis;Spondyloarthropathy;Spontaneous heparin-induced thrombocytopenia syndrome;Status epilepticus;Stevens-Johnson syndrome;Stiff leg syndrome;Stiff person syndrome;Stillbirth;Still's disease;Stoma site thrombosis;Stoma site vasculitis;Stress cardiomyopathy;Stridor;Subacute cutaneous lupus erythematosus;Subacute endocarditis;Subacute inflammatory demyelinating polyneuropathy;Subclavian artery embolism;Subclavian artery thrombosis;Subclavian vein thrombosis;Sudden unexplained death in epilepsy;Superior sagittal sinus thrombosis;Susac's syndrome;Suspected COVID-

    19;Swelling;Swelling face;Swelling of eyelid;Swollen tongue;Sympathetic ophthalmia;Systemic lupus erythematosus;Systemic lupus erythematosus disease activity index abnormal;Systemic lupus erythematosus disease activity index decreased;Systemic lupus erythematosus disease activity index increased;Systemic lupus erythematosus rash;Systemic scleroderma;Systemic sclerosis pulmonary;Tachycardia;Tachypnoea;Takayasu's arteritis;Temporal lobe epilepsy;Terminal ileitis;Testicular autoimmunity;Throat tightness;Thromboangiitis

    obliterans;Thrombocytopenia;Thrombocytopenic purpura;Thrombophlebitis;Thrombophlebitis migrans;Thrombophlebitis

    FDA-CBER-2021-5683-0000090

    Page 37

    neonatal;Thrombophlebitis septic;Thrombophlebitis superficial;Thromboplastin antibody positive;Thrombosis;Thrombosis corpora cavernosa;Thrombosis in device;Thrombosis mesenteric vessel;Thrombotic cerebral infarction;Thrombotic microangiopathy;Thrombotic stroke;Thrombotic thrombocytopenic purpura;Thyroid disorder;Thyroid stimulating immunoglobulin increased;Thyroiditis;Tongue amyloidosis;Tongue biting;Tongue oedema;Tonic clonic movements;Tonic convulsion;Tonic posturing;Topectomy;Total bile acids increased;Toxic epidermal necrolysis;Toxic leukoencephalopathy;Toxic oil syndrome;Tracheal obstruction;Tracheal oedema;Tracheobronchitis;Tracheobronchitis mycoplasmal;Tracheobronchitis viral;Transaminases abnormal;Transaminases increased;Transfusion-related alloimmune neutropenia;Transient epileptic amnesia;Transverse sinus thrombosis;Trigeminal nerve paresis;Trigeminal neuralgia;Trigeminal palsy;Truncus coeliacus thrombosis;Tuberous sclerosis complex;Tubulointerstitial nephritis and uveitis syndrome;Tumefactive multiple sclerosis;Tumour embolism;Tumour thrombosis;Type 1 diabetes mellitus;Type I hypersensitivity;Type III immune complex mediated reaction;Uhthoff's phenomenon;Ulcerative keratitis;Ultrasound liver abnormal;Umbilical cord thrombosis;Uncinate fits;Undifferentiated connective tissue disease;Upper airway obstruction;Urine bilirubin increased;Urobilinogen urine decreased;Urobilinogen urine increased;Urticaria;Urticaria papular;Urticarial vasculitis;Uterine rupture;Uveitis;Vaccination site thrombosis;Vaccination site vasculitis;Vagus nerve paralysis;Varicella;Varicella keratitis;Varicella post vaccine;Varicella zoster gastritis;Varicella zoster oesophagitis;Varicella zoster pneumonia;Varicella zoster sepsis;Varicella zoster virus infection;Vasa praevia;Vascular graft thrombosis;Vascular pseudoaneurysm thrombosis;Vascular purpura;Vascular stent thrombosis;Vasculitic rash;Vasculitic ulcer;Vasculitis;Vasculitis gastrointestinal;Vasculitis necrotising;Vena cava embolism;Vena cava thrombosis;Venous intravasation;Venous recanalisation;Venous thrombosis;Venous thrombosis in pregnancy;Venous thrombosis limb;Venous thrombosis neonatal;Vertebral artery thrombosis;Vessel puncture site thrombosis;Visceral venous thrombosis;VIth nerve paralysis;VIth nerve paresis;Vitiligo;Vocal cord paralysis;Vocal cord paresis;Vogt-Koyanagi-Harada disease;Warm type haemolytic anaemia;Wheezing;White nipple sign;XIth nerve paralysis;X-ray hepatobiliary abnormal;Young's syndrome;Zika virus associated Guillain Barre syndrome.

    FDA-CBER-2021-5683-0000091
     
  9. Dan2

    Dan2 Pedantic schlub

    "APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST

    ...SARS-CoV-2 test negative"

    Is that document meant to be a joke?
     
    Last edited: Dec 6, 2021
    GavinH likes this.
  10. Jack Kruse

    Jack Kruse Administrator

    This is another project I participated in this year about medical tyranny. Have a listen. My belief is that vaccine safety has to have the same safety testing as drug have. They don't. That concerns me as a physician.
    THE VAX ISSUE FOR ME IS SIMPLE: The issue is not the efficacy of vaccines but the vaccine obligation. Why are they mandatory when they have no undergone RCT or double-blind testing like any other drug? Why "confuse" two subjects so differently? The only reason I can come up with is the profit of Big Pharma and the CDC. We should treat vaccines like drugs. Test them with vax vs unvaxxed trials to see if they are safe. We should pursue purpose over profit as clinicians, not the other way around. We always need to employ the precautionary principle when we really do not know the efficacy vs safety curve for anything we advocate. https://www.bothell-reporter.com/na...iew-exposing-the-whole-global-pandemic-truth/
     
  11. New Zealand - so how are they doing?

    After this latest vaccine campaign -> Not so good
    upload_2021-12-6_7-24-53.png
    upload_2021-12-6_7-25-9.png

    One thing to note is the 28 day incubation to the viral load reaction within the human, also known as Pressure Selection. As the vaccine ramp up in July steepens, cases in late August thru September's increase; then as October's fully vaccine ramp up steepens, mid November thru December cases go up.
    The question of "medical & political" interest(s) -> what variants can we blame?


    upload_2021-12-6_7-25-34.png

    Sources:
    https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-data-and-statistics/covid-19-current-cases
     
    Last edited: Dec 6, 2021
    GavinH and Richard Watson like this.
  12. Perhaps I'm just different, I chose not to go into medicine almost 50 years ago not just because I didn't have the money for medical schooling; but my study of medical treatment back then did not show favorable outcomes for basic disease(s) say: cancer, CVD, etc. What I did find positive were medically unapproved treatments carried out by MDs who employed "alternative" treatments. The history of the AMA and other "licensing" agencies levied against these doctors were: loss of license(s) to practice, fines for practicing unapproved treatments. These were documented in the literature since the turn of the 19th century. Many of my sources came from the Journal of The Nature Hygienic Society; examples of these publications:



    From a "review" at that time of medical education, I found most disease identification and treatment were specific to drug intervention, for which the success rate was not good even back then.

    There was no confusion in my mind that the purpose of the AMA was self interested in making as many long term drug dependent customers as possible before they died; and if possible, extend their life even at the expense of the quality of life.
     
    Last edited: Dec 6, 2021
    GavinH, caroline, Dan2 and 3 others like this.
  13. Jacks

    Jacks Gold

    Which episode do you feature in @Jack Kruse ?
     
  14. mRNA inventor stands with Abp. Viganò’s call for alliance against ‘fundamentally evil’ COVID tyranny

    Archbishop Viganò challenged “rulers, political and religious leaders, intellectuals and all people of good will, inviting them to unite in an alliance that launches an anti-globalist manifesto, refuting point by point the errors and deviations of the dystopia of the New World Order and proposing concrete alternatives for a political program inspired by the common good, the moral principles of Christianity, traditional values, the protection of life and the natural family, the protection of business and work, the promotion of education and research, and respect for creation.”

    upload_2021-12-7_15-9-34.png

    “Our enemy is not a virus, but the insanity of those who betray their duties to the detriment of the community. This global betrayal must be stopped: let’s respond to corruption with honesty, to lies with truth, to self-interest with generous dedication to public affairs, to the desire for power and money with selfless service. Let’s go back to being proud defenders of traditional values: God, Nation, Family and Prayer”.

    As Germany Announces New Totalitarian Repression on the Pretext of COVID, Archbishop Viganò Issues Message in Support of Truth for Health Foundation
    https://catholicfamilynews.com/blog...ge-in-support-of-truth-for-health-foundation/

    Preach it !
     
    Last edited: Dec 7, 2021
  15. Richard Watson likes this.
  16. GavinH

    GavinH Gavin Horner

    Yes I believe so.
     
    caroline likes this.
  17. SHAMEfull -> Chief Officer Mike Reynolds !


    https://www.arkansasonline.com/news/2021/sep/08/man-refusing-to-wear-mask-at-fayetteville-city/
     
    GavinH likes this.

Share This Page